Home News Rivaroxaban reduces limb events after revascularization in patients with renal impairment back to News
minute read
In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced the primary composite endpoint, driven by a marked reduction in limb events, according to data from the VOYAGER PAD trial.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
